Losing British drug giant AstraZeneca from the London Stock Exchange would be a “devastating blow”, Tory former chancellor ...

AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Shares of clinical-stage company Summit Therapeutics SMMT rose nearly 9% on Thursday following a report issued by Bloomberg, ...

Citi downgraded Man Group on Wednesday to 'neutral' from 'buy' and slashed its price target on the stock to 185.0p from ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

On the valuation front, AstraZeneca currently trades at a forward price-to-earnings (P/E) ratio of 15.5, which is lower than ...

The fallers board was led by WPP, which slumped by 16% to its lowest level since 2009 after the marketing and advertising ...

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...